BioMarin's Dwarfism Therapy Gets FDA Nod for Expanded Use

The US health regulator has approved the expanded use of BioMarin Pharmaceutical's once-daily injection to treat children under the age of 5 with the most common form of short-limbed dwarfism.
Reuters Health Information

source https://www.medscape.com/s/viewarticle/997595?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?